Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · IEX Real-Time Price · USD
26.03
+0.18 (0.70%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Anika Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Anika Therapeutics stock have an average target of 30.5, with a low estimate of 24 and a high estimate of 37. The average target predicts an increase of 17.17% from the current stock price of 26.03.
Analyst Consensus: Buy
* Price targets were last updated on May 29, 2024.
Analyst Ratings
The average analyst rating for ANIK stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Hold Reiterates $24 | Hold | Reiterates | $24 | -7.80% | May 29, 2024 |
| Barrington Research | Barrington Research | Buy Maintains $37 | Buy | Maintains | $37 | +42.14% | May 9, 2024 |
| Barrington Research | Barrington Research | Buy Maintains $29 → $37 | Buy | Maintains | $29 → $37 | +42.14% | Mar 14, 2024 |
| Stephens & Co. | Stephens & Co. | Hold Reiterates $22 | Hold | Reiterates | $22 | -15.48% | Mar 14, 2024 |
| Barrington Research | Barrington Research | Buy Maintains $28 → $29 | Buy | Maintains | $28 → $29 | +11.41% | Jan 3, 2024 |
Financial Forecast
Revenue This Year
174.26M
from 166.66M
Increased by 4.56%
Revenue Next Year
185.53M
from 174.26M
Increased by 6.47%
EPS This Year
-0.11
from -5.64
EPS Next Year
0.59
from -0.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 180.1M | 196.4M | 206.1M | 226.4M | 247.1M |
| Avg | 174.3M | 185.5M | 197.5M | 219.9M | 240.0M |
| Low | 166.6M | 175.7M | 187.1M | 211.3M | 230.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.1% | 12.7% | 11.1% | 14.6% | 12.4% |
| Avg | 4.6% | 6.5% | 6.4% | 11.4% | 9.1% |
| Low | -0.0% | 0.8% | 0.8% | 7.0% | 4.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.19 | 0.97 | 0.75 | 1.12 | 1.50 |
| Avg | -0.11 | 0.59 | 0.64 | 1.09 | 1.46 |
| Low | -0.44 | 0.30 | 0.53 | 1.05 | 1.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 26.0% | 76.2% | 37.6% |
| Avg | - | - | 7.8% | 71.2% | 33.6% |
| Low | - | - | -10.5% | 64.5% | 28.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.